Effects of Dopamine Agonists on Neuropsychiatric Symptoms of Parkinson’s Disease

Publisher： Karger

E-ISSN： 1660-2862|7|1-3|206-209

ISSN： 1660-2854

Source： Neurodegenerative Diseases, Vol.7, Iss.1-3, 2010-03, pp. : 206-209

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dissociating the Cognitive Effects of Levodopa versus Dopamine Agonists in a Neurocomputational Model of Learning in Parkinson’s Disease

By  

Neurodegenerative Diseases, Vol. 11, Iss. 2, 2012-10 ,pp. : 102-111

Karger

Access to resources Recommend Favorite

Basic Research on Dopamine in Parkinson’s Disease and the Discovery of the Nigrostriatal Dopamine Pathway: The View of an Eyewitness

By  

Neurodegenerative Diseases, Vol. 5, Iss. 3-4, 2008-03 ,pp. : 114-117

Karger

Access to resources Recommend Favorite

The proto-oncogene Bcl-2 inhibits cellular toxicity of dopamine: possible implications for Parkinson‘s Disease

By Ziv I.  

Apoptosis, Vol. 2, Iss. 2, 1997-01 ,pp. : 149-155

Springer Publishing Company

Access to resources Recommend Favorite

An Autoradiographic Study on the Pathogenesis of Levodopa-Induced Dyskinesia: Regulation of Dopamine Transporter by Levodopa in a Rat Model of Parkinson’s Disease

By  

Neurodegenerative Diseases, Vol. 9, Iss. 1, 2011-08 ,pp. : 11-17

Karger

Access to resources Recommend Favorite

Parkinson’s disease: clinical aspects

By Klockgether Thomas  

Cell and Tissue Research, Vol. 318, Iss. 1, 2004-10 ,pp. : 115-120

Springer Publishing Company

Access to resources Recommend Favorite